Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors

Cecilia Lezcano; Chung‐Wei Lee; Allison R. Larson; Alexander M. Menzies; Richard Kefford; John F. Thompson; Martín C. Mihm; Shuji Ogino; Georgina V. Long; Richard A Scolyer; Gëorge F. Murphy

doi:10.1038/modpathol.2013.226

Related publications

Letter2009

High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma

Yasufumi Goto, Takaaki Arigami, Rajmohan Murali, Richard A Scolyer, Atsushi Tanemura, Minoru Takata, Roderick R. Turner, Linhda Nguyen, Tung Nguyen, Donald L. Morton, Soldano Ferone, Dave S.�B. Hoon

Article2024

Tumor necrosis as a biomarker for response to neoadjuvant therapy in pancreatic cancer

Masatoshi Kudo, Masahiro Sugimoto, S. Kobayashi, M. Konishi, Naoto Gotohda

Article2025

1617P Leucine-rich 2 glycoprotein 1 (LRG1) as potential systemic biomarker for response to neoadjuvant immune checkpoint blockade in stage III melanoma

Shizhen Chen, C.C.E. De Schrijver, H. Van Rossum, Theodora C. Linders, Lianne Hoeijmakers, M.W. Lucas, Esmée P. Hoefsmit, Irene L. M. Reijers, Petros Dimitriadis, B. van de Wiel, Karin E. de Visser, Astrid A.M. van der Veldt, Helena Eriksson, Geke A.P. Hospers, Richard A Scolyer, Karijn P.M. Suijkerbuijk, Ellen Kapiteijn, A.M. Menzies, G.V. Long, Christian U. Blank

Article2014

Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients

Matteo S. Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Suzanah C. Boyd, Mal Irvine, Adnan Nagrial, Richard A Scolyer, Richard Kefford, Georgina V. Long, Helen Rizos

Article2011

804 ORAL Evaluation of Plasma VEGFA as a Potential Predictive Pan-tumour Biomarker for Bevacizumab

Gordon C. Jayson, SL de Haas, Paul Delmar, D.W. Miles, M.A. Shah, Eric Van Cutsem, Peter Carmeliet, Poornima Hegde, Norbert Wild, S.J. Scherer